The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder.

IF 4.8 2区 医学 Q1 UROLOGY & NEPHROLOGY
Daniele Robesti, Marco Moschini, Nazario Pio Tenace, Giusy Burgio, Chiara Re, Riccardo Leni, Mario De Angelis, Pietro Scilipoti, Francesco Pellegrino, Donato Cannoletta, Giorgio Gandaglia, Nicola Fossati, Andrea Gallina, Claudio Doglioni, Maurizio Colecchia, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Roberta Lucianò
{"title":"The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder.","authors":"Daniele Robesti, Marco Moschini, Nazario Pio Tenace, Giusy Burgio, Chiara Re, Riccardo Leni, Mario De Angelis, Pietro Scilipoti, Francesco Pellegrino, Donato Cannoletta, Giorgio Gandaglia, Nicola Fossati, Andrea Gallina, Claudio Doglioni, Maurizio Colecchia, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Roberta Lucianò","doi":"10.1016/j.euf.2024.06.007","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Pathological features in non-muscle-invasive bladder cancer specimens are pivotal in determining correct patients' therapeutic management. Sparse data exist regarding the importance of second opinion performed by an expert uropathologist. This study aimed to assess the importance of a second opinion by an expert uropathologist in the management of bladder cancer.</p><p><strong>Methods: </strong>The study relied on 272 bladder cancer specimens from 231 patients seeking a pathology second opinion after transurethral resection of the bladder for a clinical suspicion of bladder cancer, relapse, or second-look procedure. Pathology second opinion was offered by an experienced fellowship-trained uropathologist. Discrepancies were recorded considering primary tumor staging, the presence of muscularis propria, and the presence of histological variants. Cases were categorized as no significant discordance, major discordance without management change, and major discordance with management change according to the European Urology Association (EAU) guidelines.</p><p><strong>Key findings and limitations: </strong>Among 272 second opinion cases, 39% (108/272) had major discordance and 28% (75/272) had major discordance with change in management according to the EAU guidelines. Upstaging and downstaging were reported in 66 (24%) patients. Improper identification of the presence of muscularis propria was found in 46 (17%) cases, of which 11 (4%) were deemed clinically relevant. Differences regarding the presence of histological variants were diagnosed in 40 cases (15%), resulting in eight (3%) changes in clinical management. In ten specimens (4%), multiple clinically relevant discrepancies were found.</p><p><strong>Conclusions and clinical implications: </strong>The second opinion evaluation changed the clinical management in 25% of the cases. These results support the importance of specimen review by an expert uropathologist as a major driver in the correct bladder cancer management.</p><p><strong>Patient summary: </strong>We investigated the importance of a second opinion performed by an expert uropathologist in the management of bladder cancer. We found that 25% had their treatment plan changed due to the revised pathological report.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology focus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euf.2024.06.007","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Pathological features in non-muscle-invasive bladder cancer specimens are pivotal in determining correct patients' therapeutic management. Sparse data exist regarding the importance of second opinion performed by an expert uropathologist. This study aimed to assess the importance of a second opinion by an expert uropathologist in the management of bladder cancer.

Methods: The study relied on 272 bladder cancer specimens from 231 patients seeking a pathology second opinion after transurethral resection of the bladder for a clinical suspicion of bladder cancer, relapse, or second-look procedure. Pathology second opinion was offered by an experienced fellowship-trained uropathologist. Discrepancies were recorded considering primary tumor staging, the presence of muscularis propria, and the presence of histological variants. Cases were categorized as no significant discordance, major discordance without management change, and major discordance with management change according to the European Urology Association (EAU) guidelines.

Key findings and limitations: Among 272 second opinion cases, 39% (108/272) had major discordance and 28% (75/272) had major discordance with change in management according to the EAU guidelines. Upstaging and downstaging were reported in 66 (24%) patients. Improper identification of the presence of muscularis propria was found in 46 (17%) cases, of which 11 (4%) were deemed clinically relevant. Differences regarding the presence of histological variants were diagnosed in 40 cases (15%), resulting in eight (3%) changes in clinical management. In ten specimens (4%), multiple clinically relevant discrepancies were found.

Conclusions and clinical implications: The second opinion evaluation changed the clinical management in 25% of the cases. These results support the importance of specimen review by an expert uropathologist as a major driver in the correct bladder cancer management.

Patient summary: We investigated the importance of a second opinion performed by an expert uropathologist in the management of bladder cancer. We found that 25% had their treatment plan changed due to the revised pathological report.

经尿道膀胱切除术时第二意见专家病理审查对患者管理的影响。
背景和目的:非肌层浸润性膀胱癌标本的病理特征对于确定患者的正确治疗方案至关重要。关于由泌尿病理专家提供第二意见的重要性的数据很少。本研究旨在评估泌尿病理专家的第二意见在膀胱癌治疗中的重要性:研究依据的是 231 名患者的 272 份膀胱癌标本,这些患者在经尿道膀胱切除术后因临床怀疑患有膀胱癌、复发或进行二诊手术而寻求病理第二意见。病理第二意见由经验丰富、受过研究培训的泌尿病理学家提供。根据原发肿瘤分期、是否存在固有肌以及是否存在组织学变异等因素记录差异。根据欧洲泌尿外科协会(EAU)的指导方针,病例被分为无重大分歧、无管理改变的重大分歧和有管理改变的重大分歧:在272例第二意见病例中,39%(108/272)存在重大不一致,28%(75/272)存在重大不一致并根据欧洲泌尿外科协会指南改变了治疗方案。66例(24%)患者报告了上行分期和下行分期。46例(17%)患者的固有肌被误诊,其中11例(4%)被认为与临床相关。有 40 例(15%)患者被诊断出存在组织学变异,其中 8 例(3%)改变了临床治疗方案。在 10 份标本(4%)中,发现了多个与临床相关的差异:第二意见评估改变了25%病例的临床治疗方案。这些结果支持了由泌尿病理专家进行标本审查的重要性,它是正确处理膀胱癌的主要驱动力。患者总结:我们调查了由泌尿病理专家进行第二意见评估在膀胱癌处理中的重要性。我们发现,25% 的患者因病理报告的修改而改变了治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European urology focus
European urology focus Medicine-Urology
CiteScore
10.40
自引率
3.70%
发文量
274
审稿时长
23 days
期刊介绍: European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信